MG
ADPT icon

Michael Gelband’s Adaptive Biotechnologies ADPT Stock Holding History

Michael Gelband’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,100
Closed -$734K – 1908
2020
Q3 		$734K Sell
15,100
-8,300
-35% -$349K 0.01% 819
2020
Q2 		$1.13M Buy
+23,400
New +$853K 0.03% 679

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Michael Gelband's ADPT Position: Q2 2026 in Review

Michael Gelband reduced its Adaptive Biotechnologies (ADPT) stake by 6.6% in Q2 2026, selling an estimated $565K and leaving 518,146 shares worth $11.1M. The position accounts for 0.07% of the portfolio, ranked #266.

Michael Gelband first reported a position in ADPT in Q2 2019 and has held it in 17 quarters since. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Michael Gelband held 518,146 shares of Adaptive Biotechnologies worth $11.1M as of Q2 2026.
  • Michael Gelband sold 36,874 Adaptive Biotechnologies shares in Q2 2026, an estimated $565K.
  • Adaptive Biotechnologies made up 0.07% of Michael Gelband's portfolio in Q2 2026, its #266 holding.
  • Michael Gelband first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 17 quarters since.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.